Recent Research Funding

Faculty secure several million dollars annually for their research from various public and private sources, including the National Institutes of Health, U.S. Food and Drug Administration, National Multiple Sclerosis Society, foundations and pharmaceutical firms.

Ralph Benedict, PhD

  • The effects of working memory training on brain function, structure, and cognition in MS. Ralph Benedict (Co-Investigator), Thomas Covey (Co-Principal Investigator), Michael Dwyer, III (Co-Investigator), David Shucard (Co-Principal Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • Fall risk and incidence reduction in multiple sclerosis. Ralph Benedict (Co-Investigator). National Multiple Sclerosis Society. 10/1/2014-9/1/2017.
  • Does working memory training improve brain function and cognition in MS?. Ralph Benedict (Co-Investigator), David Shucard (Co-Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator). National Multiple Sclerosis Society. $44,000. 9/1/2014-8/1/2015.
  • The effect of aerobic exercise on cognition in multiple sclerosis. Ralph Benedict (Co-Investigator). National Multiple Sclerosis Society. 8/1/2013-7/1/2018.
  • Effects of adenocorticotropic hormone (Acthar gel®) on recovery from cognitive relapses in MS. Ralph Benedict (Principal Investigator). Questcor. 8/1/2013-7/1/2016.
  • Oligodendrocyte Progenitor Cell Delivery for Restoration of Function in Multiple Sclerosis. Ralph Benedict (Co-Investigator). New York State Health Department. 3/1/2013-2/1/2016.

Thomas Covey, PhD

  • The effects of Post-Traumatic Stress Disorder (PTSD) symptoms on behavioral, psychological, and neurophysiological measures of decision making in police officers. Thomas Covey (Co-Principal Investigator), David Shucard (Co-Principal Investigator), Janet Shucard (Principal Investigator). National Institutes of Justice. $814,158. 1/1/2018-1/1/2020.
  • The effects of working memory training on brain function, structure, and cognition in MS. Thomas Covey (Co-Principal Investigator), Ralph Benedict (Co-Investigator), Michael Dwyer, III (Co-Investigator), David Shucard (Co-Principal Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • Neurocognitive, electrophysiological and MRI changes associated with low level laser therapy (photobiomodulation) in the treatment of Traumatic Brain Injury: A pilot study. Thomas Covey (Co-Investigator), Praveen Arany (Principal Investigator), Thomas Mang (Co-Principal Investigator), David Shucard (Co-Principal Investigator). American Society for Laser Medicine and Surgery. $68,000. 10/1/2016-11/1/2017.

Michael Dwyer, III, PhD

Osman Farooq, MD

Thomas Guttuso, Jr., MD

  • Effect of 2.5 years of rasagiline therapy on progression of cognitive biomarkers assessed by MRI in Parkinson’s disease. Thomas Guttuso, Jr. (Principal Investigator). Teva Pharmaceuticals. $150,929. 5/1/2014-4/1/2016.
  • Comparison of gabapentin and ondansetron for treating hyperemesis gravidarum. Thomas Guttuso, Jr. (Principal Investigator). NIH. $1,318,409. 1/1/2014-12/1/2017.

Thomas Langan, MD

  • Lysosomal Disease Network (U54) NINDS. Local PI. Thomas Langan (Co-Investigator). 9/1/2014-8/1/2019.

David Lichter, MBChB, FRACP

  • Dopamine Neurotransmission in Tourette Syndrome. David Lichter (Co-Investigator). NINDS. $3,593,627. 12/1/2012-11/1/2017.

David Shucard, PhD FAASM

  • The effects of Post-Traumatic Stress Disorder (PTSD) symptoms on behavioral, psychological, and neurophysiological measures of decision making in police officers. David Shucard (Co-Principal Investigator), Thomas Covey (Co-Principal Investigator), Janet Shucard (Principal Investigator). National Institutes of Justice. $814,158. 1/1/2018-1/1/2020.
  • The effects of working memory training on brain function, structure, and cognition in MS. David Shucard (Co-Principal Investigator), Ralph Benedict (Co-Investigator), Thomas Covey (Co-Principal Investigator), Michael Dwyer, III (Co-Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • Neurocognitive, electrophysiological and MRI changes associated with low level laser therapy (photobiomodulation) in the treatment of Traumatic Brain Injury: A pilot study. David Shucard (Co-Principal Investigator), Praveen Arany (Principal Investigator), Thomas Covey (Co-Investigator), Thomas Mang (Co-Principal Investigator). American Society for Laser Medicine and Surgery. $68,000. 10/1/2016-11/1/2017.
  • Does working memory training improve brain function and cognition in MS?. David Shucard (Co-Investigator), Ralph Benedict (Co-Investigator), Janet Shucard (Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator). National Multiple Sclerosis Society. $44,000. 9/1/2014-8/1/2015.

Janet Shucard, PhD

  • The effects of Post-Traumatic Stress Disorder (PTSD) symptoms on behavioral, psychological, and neurophysiological measures of decision making in police officers. Janet Shucard (Principal Investigator), Thomas Covey (Co-Principal Investigator), David Shucard (Co-Principal Investigator). National Institutes of Justice. $814,158. 1/1/2018-1/1/2020.
  • The effects of working memory training on brain function, structure, and cognition in MS. Janet Shucard (Principal Investigator), Ralph Benedict (Co-Investigator), Thomas Covey (Co-Principal Investigator), Michael Dwyer, III (Co-Investigator), David Shucard (Co-Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator), Robert Zivadinov (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • Does working memory training improve brain function and cognition in MS?. Janet Shucard (Principal Investigator), Ralph Benedict (Co-Investigator), David Shucard (Co-Investigator), Bianca Weinstock-Guttman (Co-Investigator). National Multiple Sclerosis Society. $44,000. 9/1/2014-8/1/2015.

Kinga Szigeti, MD, PhD

  • 2.Olfactory Receptor copy number variation association with age at onset of Alzheimer disease. Kinga Szigeti (Principal Investigator). NIA. $853,565. 9/1/2010-8/1/2015.

Bianca Weinstock-Guttman, MD

Gil Wolfe, MD, FAAN

  • PROMISE-MG: Prospective multicenter observational cohort study of comparative. Gil Wolfe (Co-Investigator). PCORI. $7,200. 1/1/2018-12/1/2019.
  • International Myasthenia Gravis Treatment Guideline. Gil Wolfe (Co-Principal Investigator). MG Foundation of America. $25,000. 3/1/2014-8/1/2015.
  • Network of Excellence in Neuroscience Clinical Trial: NeuroNEXT. Gil Wolfe (Principal Investigator). NIH/NINDS. $1,500,000. 9/1/2011-8/1/2018.

Lawrence Wrabetz, MD

  • Grants and Sponsored Research(selected). Lawrence Wrabetz (Principal Investigator). 12/1/2007-12/1/2020.

Robert Zivadinov, MD, PhD

  • The effects of working memory training on brain function, structure, and cognition in MS. Robert Zivadinov (Co-Investigator), Ralph Benedict (Co-Investigator), Thomas Covey (Co-Principal Investigator), Michael Dwyer, III (Co-Investigator), Janet Shucard (Principal Investigator), David Shucard (Co-Principal Investigator), Bianca Weinstock-Guttman (Co-Investigator). National Multiple Sclerosis Society. $622,839. 6/1/2017-6/1/2020.
  • Cholesterol Biomarkers and Oxysterols in Multiple Sclerosis Progression. Robert Zivadinov (Co-Investigator). NINDS. 7/1/2016-7/1/2018.
  • Physiological mechanisms of a biomarker of recovery from concussion. Robert Zivadinov (Co-Investigator). National Institute of Health. 4/1/2016-4/1/2021.
  • Delay discounting as a target for self-regulation in prediabetes. Robert Zivadinov (Co-Investigator). National Institute of Health. 10/1/2015-10/1/2020.
  • Effect of teriflunomide (Aubagio) on cortico-basal ganglionic thalamo cortical gray matter connectivity in the Theiler's Murine Encephalomyelitis Virus model of demyelination. Robert Zivadinov (Principal Investigator). Genzyme, Inc. 12/1/2014-12/1/2016.
  • Do higher vitamin A levels improve disease severity progression in relapsing, remitting patients on either glatiramer acetate or interferono-beta disease modifying therapies and normal vitamin D levels. Robert Zivadinov (Co-Investigator). Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. 10/1/2014-12/1/2016.
  • Effect of teriflunomide (Aubagio) on the prevention of gray matter of gray matter atrophy progression in clinically isolated syndrome patients. The post-hoc, blinded MRI analysis of TOPIC study using advanced MRI assessments. Robert Zivadinov (Co-Principal Investigator). Genzyme, Inc. 9/1/2014-12/1/2015.
  • NeuroSTREAM - Neurological Software Tool for Reliable Atrophy Measurement. Robert Zivadinov (Co-Principal Investigator), Michael Dwyer, III (Principal Investigator). Novartis, Inc. 8/1/2014-12/1/2015.
  • Intra-arterial Vaospasm trial; A multi-center prospective randomized study. Robert Zivadinov (Co-Principal Investigator). The University of Texas Health Science Center at Houston. 6/1/2014-12/1/2016.
  • MRI services for double-blind, randomized, parallel-group, multicenter study comparing safety and efficacy of monotherapy with INT131 1 mg or 3 mg administered orally or placebo once daily in treatment naive patients with relapsing/remitting MS. Robert Zivadinov (Co-Principal Investigator). Intekrin. 5/1/2014-12/1/2016.
  • MRI services for Cerebral Protection in Transcatheter Aortic Valve Replacement - The SENTINEL study. Robert Zivadinov (Principal Investigator). Claret Medical. 4/1/2014-12/1/2016.
  • A prospective, observational, single-blinded, longitudinal optical coherence tomography study of the effect of glatiramer acetate on retinal nerve fiber layer thickness in patients with relapsing-remitting multiple sclerosis over 24 months. Robert Zivadinov (Principal Investigator). TEVA Pharmaceuticals, Inc. 12/1/2013-12/1/2015.
  • Defining the hierarchy of the anatomic, physiologic, and metabolic neuro-degenerative changes in optic neuritis and multiple sclerosis. Robert Zivadinov (Co-Principal Investigator). Neuro-Ophthalmologic Associates, PC. 12/1/2013-12/1/2016.
  • MRI analysis of the brain damage occurring with the use of a cerebral protection system in patients undergoing trans-femoral aortic valve implantation. Robert Zivadinov (Co-Principal Investigator). Claret Medical. 11/1/2013-12/1/2015.
  • Hyperbaric Oxygen therapy for Multiple Sclerosis Relapse. Robert Zivadinov (Co-Investigator). SUNY Stony Brook. 10/1/2013-12/1/2016.
  • The effect of teriflunomide (Aubagio) on gray matter pathology in multiple sclerosis; A 12-month prospective, observational, single-blinded, longitudinal study. Robert Zivadinov (Principal Investigator). Genzyme, Inc. 6/1/2013-12/1/2015.
  • An open-label, prospective, observational, single-blinded,longitudinal, cross-over study to evaluate the effect of switching from daily injections of 20 mg glatiramer acetate (GA) to 40mg GA three times per week on thalamic path. in subjects with RRMS. Robert Zivadinov (Principal Investigator). TEVA Pharmaceuticals, Inc. 6/1/2013-12/1/2017.
  • Open-label, single-blinded, observational, prospective, 24-month, longitudinal, controlled study to assess the efficacy of fingolimod (Gilenya) on development of thalamus pathology and cognitive impairment in patients with RRMS. Robert Zivadinov (Principal Investigator). Novartis, Inc. 6/1/2013-12/1/2017.
  • Lipoprotein and lipid metabolism in multiple sclerosis disease progression. Robert Zivadinov (Principal Investigator). National Multiple Sclerosis Society. 3/1/2013-12/1/2016.
  • Open-label, single-blinded, observational, prospective, 1-year follow-up, controlled study to assess the efficacy of fingolimod (Gilenya) on remyelination and demelynation in patients with relapsing forms of multiple sclerosis. Robert Zivadinov (Principal Investigator). Novartis, Inc. 5/1/2012-12/1/2015.